



Pharmaceutical Services, 2 Franklin Street, Belfast BT2 8DQ
Telephone No. 028 95 36 0333

Medicine Supply Notification: Methylprednisolone (Medrone®) 100mg tablets

Tier 2 – medium impact

Date of issue: 01/09/2026

[Medicines Supply Tool – SPS - Specialist Pharmacy Service – The first stop for professional medicines advice](#)

Summary

- Methylprednisolone (Medrone®) 100mg tablets are out of stock until w/c 5 October 2026.
- Methylprednisolone 500mg and 1000mg powder for solution for injections remain available and can support increased demand.
- Unlicensed imports of methylprednisolone 100mg tablets have been sourced, lead times vary.

ACTIONS REQUIRED

Specialists should:

- consider prescribing methylprednisolone 500mg or 1000mg powder for solution for injection if suitable, ensuring that the patient is not intolerant to any of the excipients. This will have service implications for secondary care; and
- where the injection is not appropriate, consider prescribing unlicensed methylprednisolone 100mg tablets. Prescribers should work with pharmacy teams to ensure orders are placed within appropriate time frames as lead times may vary (see Supporting information below).

Prescribers in primary care treating patients affected by the shortage should contact the secondary care specialist team to discuss the management plan. The team can prescribe unlicensed methylprednisolone 100mg tablets for patients having difficulty accessing this in primary care.

Supporting information

Clinical Information

Methylprednisolone is a potent corticosteroid. It is indicated for conditions requiring glucocorticoid activity. This includes treatment of relapse in multiple sclerosis where a 500mg tablet is administered once daily for 5 days, or a 1g intravenous infusion is administered once daily for 3–5 days.



Guidance on ordering and prescribing unlicensed imports

The following specialist importers have confirmed they can source unlicensed methylprednisolone 100mg tablets. Please note there may be other companies that can also source supplies:

- Alium Medical
- Arcadia Medical
- Genetech
- Mawdsley's unlicensed
- Smartway Pharma
- Tanner Pharma
- Uniphar

Any decision to prescribe an unlicensed medicine must consider the relevant guidance and NHS Trust or local governance procedures. Unlicensed imports do not undergo any central quality assessment or suitability evaluation. Therefore, any import must be locally assessed in line with local unlicensed medicines processes.

Please see the links below for further information:

- The supply of unlicensed medicinal products, Medicines and Healthcare products Regulatory Agency (MHRA) [The supply of unlicensed medicinal products special GN14.pdf](#)
- Professional Guidance for the Procurement and Supply of Specials, Royal Pharmaceutical Society [RPS publishes updated guidance for the procurement and supply of specials - The Pharmaceutical Journal](#)
- Prescribing unlicensed medicines, General Medical Council (GMC) [Prescribing unlicensed medicines - professional standards - GMC](#)

When prescribing a product that is not licensed in the UK due to a supply issue with the licensed alternative prescribers must indicate on the HS21 prescription that an unlicensed product is required, with the following wording: "special order"

Links to further information:

- Methylprednisolone (Medrone®) 100mg tablets [Medrone 100mg Tablets - Summary of Product Characteristics \(SmPC\) - \(emc\) | 1087](#)
- Methylprednisolone 500mg Powder for Solution for Injection [Methylprednisolone 500 mg Powder for Solution for Injection - Summary of Product Characteristics \(SmPC\) - \(emc\) | 100416](#)

Methylprednisolone 1000mg Powder for Solution for Injection [Methylprednisolone 1 gram Powder for Solution for Injection - Summary of Product Characteristics \(SmPC\) - \(emc\) | 100413](#)